Grifols (GIKLY) Non-Current Assets (2010 - 2025)
Grifols (GIKLY) reported Non-Current Assets of $17.0 billion for Q4 2025, up 1.71% on a YoY basis from $16.8 billion in Q4 2024, and up 1.71% quarter-over-quarter from $16.8 billion in Q4 2024.
Grifols (GIKLY) Non-Current Assets (2010 - 2025) Analysis & Trends
Grifols has reported Non-Current Assets for 16 years, with the latest figure at $17.0 billion in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets rose 1.71% year-over-year to $17.0 billion; the trailing twelve-month figure through Dec 2025 stood at $17.0 billion (up 1.71% YoY), and the FY2025 full-year result was $17.0 billion, up 31454.2% from the prior year.
- Non-Current Assets for Q4 2025 stood at $17.0 billion, up from $16.8 billion in the prior quarter.
- The five-year high for Non-Current Assets was $17.0 billion in Q4 2025, with the low at $15.7 billion in Q4 2021.
- Historically, Non-Current Assets has averaged $16.5 billion across 5 years, with a median of $16.8 billion in 2024.
- Annual changes were most pronounced in 2021 — Non-Current Assets climbed 8.73% — and 2023, when it decreased 5.24%.
- Grifols' Non-Current Assets stood at $15.7 billion in 2021, then increased by 7.48% to $16.9 billion in 2022, then fell by 5.24% to $16.0 billion in 2023, then advanced by 4.77% to $16.8 billion in 2024, then climbed by 1.71% to $17.0 billion in 2025.
- The last three Non-Current Assets figures came in at $17.0 billion (Q4 2025), $16.8 billion (Q4 2024), and $16.0 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 60.81 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Grifols | - | - | - | 17.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.04 Bn |
| Dec 31, 2024 | 16.75 Bn |
| Dec 31, 2023 | 15.99 Bn |
| Dec 31, 2022 | 16.87 Bn |
| Dec 31, 2021 | 15.70 Bn |
| Dec 31, 2020 | 14.44 Bn |
| Sep 30, 2020 | 14.02 Bn |
| Mar 31, 2020 | 13.50 Bn |
| Dec 31, 2019 | 11.27 Bn |
| Sep 30, 2019 | 11.55 Bn |
| Mar 31, 2019 | 11.25 Bn |
| Dec 31, 2018 | 10.27 Bn |
| Sep 30, 2018 | 10.18 Bn |
| Jun 30, 2018 | 10.13 Bn |
| Mar 31, 2018 | 9.72 Bn |
| Dec 31, 2017 | 9.39 Bn |
| Jun 30, 2017 | 9.09 Bn |
| Dec 31, 2016 | 7.57 Bn |
| Sep 30, 2016 | 7.38 Bn |
| Jun 30, 2016 | 7.48 Bn |